Nzoz For Med Sp. z o.o.
- Address
- lock Available on a paid plan
Digestive System Diseases
The research at Nzoz For Med Sp. z o.o. concentrates on Crohn’s disease and ulcerative colitis, evaluating new biologic agents and biosimilars to improve long‑term disease control and safety.
- Long‑term treatment outcomes with mirikizumab
- Dose‑ranging and maintenance study of TEV‑48574
- Biosimilar comparison of AVT16 versus Entyvio
- Induction and maintenance efficacy of duvakitug
With twelve active trials and six investigators, the site is advancing therapeutic options for moderate to severe inflammatory bowel disease in the European region.
Immune System Diseases
Studies at the centre explore how targeting the immune system can modulate inflammatory bowel conditions, testing agents such as vixarelimab and eltrekibart for remission induction and maintenance.
- Evaluation of vixarelimab for induction of clinical remission
- Combination therapy of eltrekibart with mirikizumab
- Safety profiling of emerging biologic therapies
- Assessment of clinical remission and endoscopic response criteria
The hospital’s focus on immune‑mediated pathways reflects its commitment to expanding treatment possibilities for patients with severe ulcerative colitis and Crohn’s disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nzoz For Med Sp. z o.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE) | Polpharma Biologics S.A. | Phase III | Not Recruiting | Nov 2023 | Apr 2026 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 6 | Unknown | 2023-03-17 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.